ProShares Ultra Nasdaq Biotechnology (BIB)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER Summary
BIB Chart
ProShares Ultra Nasdaq Biotechnology Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kevin Bresler TD Waterhouse Canada Inc. | 50 | $4,121 | $4,132.5 | $11.5 | 0.28% |
ProShares Ultra Nasdaq Biotechnology (BIB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProShares Ultra Nasdaq Biotechnology ever had a stock split?
ProShares Ultra Nasdaq Biotechnology Profile
| NASDAQ (NMS) Exchange | US Country |
Overview
The company operates as an investment fund focused on the biotechnology and pharmaceutical sectors. Managed by ProShare Advisors, it targets achieving daily returns consistent with its Daily Target by investing in financial instruments. The investments are based on a modified capitalization weighted index of Nasdaq listed companies classified in the biotechnology or pharmaceutical industries. The fund's strategy is characterized by a non-diversified approach, concentrating its investments in these high-potential sectors. This approach allows the fund to potentially capture significant gains from the biotech and pharmaceutical sectors' dynamic and innovative nature.
Products and Services
- Daily Target Investment Strategy
- Modified Capitalization Weighted Index
- Non-diversified Portfolio
The fund's core offering is its investment strategy, aimed at achieving daily returns that align with its predetermined Daily Target. This strategy is executed through precise and strategic investments in financial instruments related to the biotech and pharmaceutical sectors. By focusing on these sectors, the fund leverages the growth and volatility inherent in these industries to pursue its investment objectives.
Another cornerstone of the fund's strategy is its reliance on a modified capitalization weighted index. This index includes a selection of securities from Nasdaq listed companies classified as biotechnology or pharmaceutical. The modification of the traditional capitalization weighting approach allows the fund to potentially enhance returns by weighting its investments toward companies with higher growth prospects within these sectors.
The fund adopts a non-diversified investment strategy, focusing its portfolio on the biotechnology and pharmaceutical sectors without spreading its investments across a wide array of industries. This concentrated investment approach is designed to capitalize on the specific opportunities within these sectors, although it also involves a higher level of risk compared to more diversified investment strategies.
